CN107789373A - 茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途 - Google Patents
茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途 Download PDFInfo
- Publication number
- CN107789373A CN107789373A CN201710789742.0A CN201710789742A CN107789373A CN 107789373 A CN107789373 A CN 107789373A CN 201710789742 A CN201710789742 A CN 201710789742A CN 107789373 A CN107789373 A CN 107789373A
- Authority
- CN
- China
- Prior art keywords
- acid
- skin
- poria cocos
- purposes
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000197580 Poria cocos Species 0.000 title claims abstract description 122
- 235000008599 Poria cocos Nutrition 0.000 title claims abstract description 122
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 235000001188 Peltandra virginica Nutrition 0.000 title claims abstract description 38
- 230000029663 wound healing Effects 0.000 title claims abstract description 34
- 238000012423 maintenance Methods 0.000 title description 8
- 239000002253 acid Substances 0.000 claims abstract description 158
- 238000006356 dehydrogenation reaction Methods 0.000 claims abstract description 41
- 241000894006 Bacteria Species 0.000 claims abstract description 40
- 241001149422 Ganoderma applanatum Species 0.000 claims abstract description 38
- 238000002360 preparation method Methods 0.000 claims abstract description 33
- LADJWZMBZBVBSB-UHFFFAOYSA-N Dehydrotumulosic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC4(C)C3=CCC21 LADJWZMBZBVBSB-UHFFFAOYSA-N 0.000 claims abstract description 30
- LADJWZMBZBVBSB-YEXRKOARSA-N (2r)-2-[(3s,5r,10s,13r,14r,16r,17r)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@@]4(C)C3=CC[C@H]21 LADJWZMBZBVBSB-YEXRKOARSA-N 0.000 claims abstract description 25
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 claims abstract description 24
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 claims abstract description 24
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000011148 porous material Substances 0.000 claims abstract description 20
- IUUBODMNDCMSEU-UHFFFAOYSA-N 3-[6-amino-3-(3-hydroxypropyl)-2,4,5,9-tetrahydropurin-2-yl]propan-1-ol Chemical compound NC1=NC(CCCO)N(CCCO)C2N=CNC12 IUUBODMNDCMSEU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000002689 soil Substances 0.000 claims abstract description 17
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims description 56
- 108010035532 Collagen Proteins 0.000 claims description 56
- 229920001436 collagen Polymers 0.000 claims description 56
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 43
- 229920002674 hyaluronan Polymers 0.000 claims description 43
- 229960003160 hyaluronic acid Drugs 0.000 claims description 43
- 239000003814 drug Substances 0.000 claims description 21
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000002537 cosmetic Substances 0.000 claims description 13
- 235000013305 food Nutrition 0.000 claims description 12
- ONFPYGOMAADWAT-OXUZYLMNSA-N Dehydroeburicoic acid Chemical compound CC1(C)[C@@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@@]4(C)C3=CC[C@H]21 ONFPYGOMAADWAT-OXUZYLMNSA-N 0.000 claims description 9
- 230000032683 aging Effects 0.000 claims description 8
- 230000037303 wrinkles Effects 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 230000009759 skin aging Effects 0.000 claims description 7
- UGMQOYZVOPASJF-OXUZYLMNSA-N (2r)-2-[(3s,5r,10s,13r,14r,17r)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)CC[C@]21C UGMQOYZVOPASJF-OXUZYLMNSA-N 0.000 claims description 6
- LADJWZMBZBVBSB-HSGZZQKSSA-N 3-epidehydrotumulosic acid Chemical compound CC1(C)[C@H](O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@@]4(C)C3=CC[C@H]21 LADJWZMBZBVBSB-HSGZZQKSSA-N 0.000 claims description 6
- UGMQOYZVOPASJF-UHFFFAOYSA-N Eburicoinsaeure Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC21C UGMQOYZVOPASJF-UHFFFAOYSA-N 0.000 claims description 6
- NBSBUIQBEPROBM-GIICLEHTSA-N Trametenolic acid B Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C(O)=O)CC[C@]21C NBSBUIQBEPROBM-GIICLEHTSA-N 0.000 claims description 6
- 238000007596 consolidation process Methods 0.000 claims description 6
- 238000010612 desalination reaction Methods 0.000 claims description 6
- 230000003020 moisturizing effect Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 4
- -1 PA) Chemical compound 0.000 claims description 4
- 241001251949 Xanthium sibiricum Species 0.000 claims description 4
- NBSBUIQBEPROBM-UHFFFAOYSA-N (+)-trametenolic acid B Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)CCC21C NBSBUIQBEPROBM-UHFFFAOYSA-N 0.000 claims description 3
- RWIALJIVPUCERT-DRCQUEPLSA-N (2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3-acetyloxy-16-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound CC1(C)[C@@H](OC(C)=O)CC[C@]2(C)C3=CC[C@]4(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@@]4(C)C3=CC[C@H]21 RWIALJIVPUCERT-DRCQUEPLSA-N 0.000 claims description 3
- XADJANKGURNTIA-YEXRKOARSA-N (2r)-2-[(3s,5r,10s,13r,14r,16r,17r)-3,16-dihydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@]21C XADJANKGURNTIA-YEXRKOARSA-N 0.000 claims description 3
- RWIALJIVPUCERT-UHFFFAOYSA-N 3-Ac-(3bata,16alpha)-3,16-Dihydroxy-24-methylenelanosta-7,9(11)-dien-21-oic acid Natural products CC1(C)C(OC(C)=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC4(C)C3=CCC21 RWIALJIVPUCERT-UHFFFAOYSA-N 0.000 claims description 3
- RWIALJIVPUCERT-DRCQUEPLSA-M 3-Epidehydropachymic Acid Natural products O=C([O-])[C@H](CCC(C(C)C)=C)[C@H]1[C@H](O)C[C@]2(C)[C@]1(C)CC=C1[C@]3(C)[C@H](C(C)(C)[C@@H](OC(=O)C)CC3)CC=C21 RWIALJIVPUCERT-DRCQUEPLSA-M 0.000 claims description 3
- ONFPYGOMAADWAT-UHFFFAOYSA-N Dehydroeburicolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 ONFPYGOMAADWAT-UHFFFAOYSA-N 0.000 claims description 3
- KPKYWYZPIVAHKU-UHFFFAOYSA-N Polyporenic acid C Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC4(C)C3=CCC21 KPKYWYZPIVAHKU-UHFFFAOYSA-N 0.000 claims description 3
- KVAQLXUMUVEKGR-UHFFFAOYSA-N Poricoic acid A Natural products C1C(C(C)=C)C(C)(CCC(O)=O)C2=CCC3(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC3(C)C2=C1 KVAQLXUMUVEKGR-UHFFFAOYSA-N 0.000 claims description 3
- NXAZWYWJZDFISF-UHFFFAOYSA-N Poricoic acid B Natural products C1C(C(C)=C)C(C)(CCC(O)=O)C2=CCC3(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC3(C)C2=C1 NXAZWYWJZDFISF-UHFFFAOYSA-N 0.000 claims description 3
- XADJANKGURNTIA-UHFFFAOYSA-N Tumulosic acid Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C XADJANKGURNTIA-UHFFFAOYSA-N 0.000 claims description 3
- DVXFDXIVWQWLIU-UHFFFAOYSA-N dehydroeburiconic acid Natural products CC1(C)C(=O)CCC2(C)C3=CCC4(C)C(C(CCC(=C)C(C)C)C(O)=O)CCC4(C)C3=CCC21 DVXFDXIVWQWLIU-UHFFFAOYSA-N 0.000 claims description 3
- QFPLAAZRZNKRRY-UHFFFAOYSA-N dehydrotrametenolic acid Natural products CC1(C)C(O)CCC2(C)C3=CCC4(C)C(C(CCC=C(C)C)C(O)=O)CCC4(C)C3=CCC21 QFPLAAZRZNKRRY-UHFFFAOYSA-N 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- KVAQLXUMUVEKGR-SMFZDKLCSA-N poricoic acid A Chemical compound C1[C@@H](C(C)=C)[C@](C)(CCC(O)=O)C2=CC[C@]3(C)[C@@H]([C@@H](CCC(=C)C(C)C)C(O)=O)[C@H](O)C[C@@]3(C)C2=C1 KVAQLXUMUVEKGR-SMFZDKLCSA-N 0.000 claims description 3
- NXAZWYWJZDFISF-KXGBKNTBSA-N poricoic acid b Chemical compound C1[C@@H](C(C)=C)[C@](C)(CCC(O)=O)C2=CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C(O)=O)[C@H](O)C[C@@]3(C)C2=C1 NXAZWYWJZDFISF-KXGBKNTBSA-N 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 36
- 210000002950 fibroblast Anatomy 0.000 description 23
- 239000002798 polar solvent Substances 0.000 description 19
- 239000001963 growth medium Substances 0.000 description 18
- 238000000605 extraction Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000012930 cell culture fluid Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000001497 healthy food Nutrition 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- ICBPURKUPVLVCM-UHFFFAOYSA-N 1,5-dimethyl-2-phenylpyrazol-3-one;2-hydroxy-2-phenylacetic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1.CN1C(C)=CC(=O)N1C1=CC=CC=C1 ICBPURKUPVLVCM-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002068 microbial inoculum Substances 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 244000000000 soil microbiome Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种使用茯苓萃取物、去氢茯苓酸(DPA)、茯苓酸(PA)、去氢土莫酸(DTA)、土莫酸(TA)、猪苓酸C(PAC)、3‑表‑去氢土莫酸(EDTA)、去氢栓菌酸(DTTA)、栓菌酸(TTA)、去氢层孔菌酸(DEA)、层孔菌酸(EA)、茯苓新酸A(PAA)及/或茯苓新酸B(PAB)于制备一制剂的用途,其中该制剂用于保养肌肤及/或促进伤口愈合。
Description
技术领域
本发明关于茯苓萃取物及/或其活性成分的应用,尤其是关于使用茯苓萃取物及/或其活性成分以保养肌肤及/或促进伤口愈合的应用。其中,该茯苓萃取物及/或其活性成分通过提升胶原蛋白及/或透明质酸的表现以保养肌肤及/或促进伤口愈合。
背景技术
当肌肤的水分含量降低时,会使得肌肤表面的角质细胞因为无法正常脱落而堆积,进而使肌肤失去光泽与弹性,显得干燥、粗糙,甚至出现皱纹等肌肤老化现象。因此,若可有效提升肌肤的水分含量,将可减少前述情况的发生。
研究证实,胶原蛋白(collagen)与透明质酸(hyaluronic acid)具有提升肌肤水分含量的功能,故市面上许多添加有胶原蛋白及/或透明质酸的保养品、健康食品,都宣称可提供滋润肌肤、紧实肌肤、修复肌肤、保湿、淡化皱纹、延缓肌肤老化、及预防肌肤老化的效果。此外,胶原蛋白因具有高生物相容性、低免疫性,且可以被身体分解吸收,故也有健康食品因添加有胶原蛋白而宣称可提供促进伤口愈合的效果。
然而,近年来在世界各地爆发口蹄疫、禽流感、狂牛症等人畜共通传染病,此使得动物性胶原蛋白及透明质酸的安全性受到质疑。此外,不论是以口服、涂抹或是注射的方式以使用外源性胶原蛋白或透明质酸,都有吸收率不佳、或是可能引起免疫反应的问题。此所以,业界对于外源性胶原蛋白与透明质酸的使用,一直以来都存在相当大的争议。因此,业界目前仍积极开发可有效提升内源性胶原蛋白及/或透明质酸表现量的制剂或方法,希望通过内源性胶原蛋白及/或透明质酸的提升以达到保养肌肤及/或促进伤口愈合的效果,且避免因补充外源性胶原蛋白及/或透明质酸而引起的安全性及有效性问题。
本案发明人研究发现,茯苓萃取物及/或其活性成分可有效提升细胞内胶原蛋白、细胞外胶原蛋白、及/或细胞外透明质酸的含量,此即,茯苓萃取物及/或其活性成分可有效提升内源性胶原蛋白及/或透明质酸的含量,故可用于保养肌肤及/或促进伤口愈合。
发明内容
因此,本发明的一目的,在于提供一种使用茯苓萃取物于制备一制剂的用途,其中该制剂用于保养肌肤及/或促进伤口愈合。较佳地,该茯苓萃取物包含以下的至少一者:去氢茯苓酸(dehydropachymic acid,DPA)、茯苓酸(pachymic acid,PA)、去氢土莫酸(dehydrotumulosic acid,DTA)、土莫酸(tumulosic acid,TA)、猪苓酸C(polyporenicacid C,PAC)、3-表-去氢土莫酸(3-epi-dehydrotumulosic acid,EDTA)、去氢栓菌酸(dehydrotrametenolic acid,DTTA)、栓菌酸(trametenolic acid,TTA)、去氢层孔菌酸(dehydroeburicoic acid,DEA)、层孔菌酸(eburicoic acid,EA)、茯苓新酸A(poricoicacid A,PAA)及茯苓新酸B(poricoic acid B,PAB)。更佳地,该茯苓萃取物为茯苓皮部萃取物,其中以茯苓皮部萃取物的总重量计,茯苓新酸A及茯苓新酸B的总含量不小于40重量%。
其中,该制剂以一化妆品、保养品或食品的形式提供,且通过提升胶原蛋白及/或透明质酸的表现以保养肌肤。
其中,该化妆品、保养品及食品用于以下的至少一者:滋润肌肤、紧实肌肤、修复肌肤、保湿、淡化皱纹、延缓肌肤老化、及预防肌肤老化。
其中,该制剂以一药剂的形式提供,且通过提升胶原蛋白及/或透明质酸的表现以促进伤口愈合。
本发明的另一目的,在于提供一种使用一活性成分于制备一用于保养肌肤及/或促进伤口愈合的制剂的用途,其中该活性成分选自以下的至少一者:去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B。较佳地,该活性成分茯苓新酸A及/或茯苓新酸B。更佳地,该活性成分以萃取物的形式提供,尤其是以真菌萃取物或植物萃取物的形式提供。
较佳地,上述制剂以一化妆品、保养品、食品或药剂的形式提供,其中,该药剂通过提升胶原蛋白及/或透明质酸的表现以促进伤口愈合,该化妆品、保养品及食品提升胶原蛋白及/或透明质酸的表现以保养肌肤,用于以下的至少一者:滋润肌肤、紧实肌肤、修复肌肤、保湿、淡化皱纹、延缓肌肤老化、及预防肌肤老化。
本发明的又一目的,在于提供一种保养肌肤及/或促进伤口愈合的方法,其包含对一有需要的个体投予一有效量的上述活性成分或茯苓萃取物。
本发明的再一目的,在于提供一种保养肌肤及/或促进伤口愈合的组合物,该组合物为一化妆品、保养品、食品或药剂,且包含一有效量的上述活性成分或茯苓萃取物。
本发明的详细技术内容及部分具体实施例,将描述于以下内容中,以供本领域技术人员据以明了本发明的特征。
具体实施方式
以下将描述根据本发明的部分具体实施例;但在不背离本发明精神下,本发明还可以多种不同形式的实施例来实践,不应将本发明保护范围解释为限于说明书所陈述的。此外,除非文中有另外说明,于本说明书中(尤其是在前述权利要求书中)所使用的“一”、“该”及类似用语应理解为包含单数及复数形式;所谓“有效量”,是指投予至个体时,可有效提升该个体的胶原蛋白及/或透明质酸的表现的化合物用量;所谓“个体”是指哺乳动物,哺乳动物可为人类或非人动物;单位“毫克/公斤体重”是指每公斤体重个体所须的剂量。
如上述说明,肌肤中的水分含量降低为造成肌肤老化的一个重要原因。已知胶原蛋白是人体的结缔组织与细胞外间质中一种重要的含醣蛋白质,占人体总蛋白的20%以上。胶原蛋白以三条胜肽链缠绕成三股螺旋作为基础结构,此三股螺旋结构在皮肤纤维母细胞内合成后,会被分泌到细胞外,形成紧密的成熟胶原纤维,此结构赋予胶原蛋白保持肌肤弹性、提高肌肤保水度及促进伤口愈合的功效。透明质酸则大量存在于真皮层中,属于粘多醣类,具有高度的保湿功能,可使肌肤保持弹性、湿润,并可减少皱纹、避免肌肤老化。
茯苓药材是指拟层孔菌科真菌(Poria cocos (Schw.) Wolf)的干燥菌核。茯苓真菌常寄生在松树根上,外皮呈淡棕色或黑褐色(茯苓皮部),内部则呈粉红色或白色(茯苓肉部)。传统中医典籍记载茯苓具有镇静、利尿、营养素补充、免疫力增强及延缓老化等用途。现代医学研究也证实茯苓具有抗发炎、抗肿瘤、调节免疫系统、降血糖、促进营养吸收等功效。本案发明人研究发现,茯苓萃取物可有效促进细胞表现胶原蛋白及/或透明质酸(即,提升内源性胶原蛋白及/或透明质酸的含量),故可用于保养肌肤及促进伤口愈合。
因此,本发明提供一种使用茯苓萃取物于保养肌肤及/或促进伤口愈合的应用,包括使用茯苓萃取物制备一用于保养肌肤及/或促进伤口愈合的制剂的用途、对有需要的个体投予茯苓萃取物以保养肌肤及/或促进伤口愈合的方法、以及提供一包含茯苓萃取物的组合物。
根据本发明,所采用的茯苓萃取物可以是一通过包含如下步骤的操作所提供的粗萃物或萃取物:(a)以一第一极性溶剂萃取茯苓原料,获得一粗萃物;(b)干燥该粗萃物,获得一粗萃物粉末;(c)以一第二极性溶剂萃取该粗萃物粉末,获得茯苓萃取物。其中,该第一极性溶剂与该第二极性溶剂相同或不同,且可分别选自水、乙醇、及前述的组合。于本发明的部分实施例中,采用乙醇浓度相同或不同的乙醇水溶液作为第一极性溶剂与第二极性溶剂。
于步骤(a)中,该茯苓原料可以是茯苓皮部及/或茯苓肉部,且可视需要调整第一极性溶剂与茯苓原料的用量比率。一般而言,第一极性溶剂的用量并无特殊限制,只要可使原料均匀分散即可。举例言之,可于步骤(a)采用第一极性溶剂与茯苓原料的体积比为约8:1至约16:1的用量。于本发明一具体实施例中,以茯苓皮部作为原料,且乙醇水溶液为第一极性溶剂,并以乙醇水溶液:原料的体积比为约 8:1 的用量以进行步骤(a)的萃取。于本发明另一具体实施例中,以茯苓皮部及肉部作为原料,且乙醇水溶液为第一极性溶剂,并以乙醇水溶液:原料的体积比为约 8:1 的用量以进行步骤(a)的萃取。
于步骤(a)中,可视所采用的第一极性溶剂来选用合宜的萃取时间。以采用乙醇水溶液作为第一极性溶剂且乙醇水溶液:茯苓的体积比为 8:1为例,通常萃取历时至少1小时,较佳至少2小时,更佳至少3小时。此外,可视需要辅以例如煎煮、冷却、过滤、减压浓缩、树脂管柱层析等其它操作以进行步骤(a)。另外,可视需要于进行步骤(a)之前,先将茯苓预浸泡于第一极性溶剂中一段时间。以采用乙醇水溶液为第一极性溶剂为例,可先进行预浸泡历时例如约12小时。
于步骤(c)中,可视需要调整第二极性溶剂与由步骤(b)所获得的粗萃物粉末的用量比。一般而言,第二极性溶剂的用量并无特殊限制,只要可使粗萃物粉末均匀分散即可。举例言之,可于步骤(c)采用第二极性溶剂与茯苓粗萃物粉末的体积比为约8:1至约16:1的用量。于本发明一具体实施例中,以乙醇水溶液为第二极性溶剂,并以乙醇水溶液:茯苓粗萃物粉末的体积比为约 8:1的用量以进行步骤(c)的萃取。
根据本发明所采用的茯苓萃取物,也可以是一干燥物,此干燥物可通过干燥步骤(c)所得的萃取液而提供。为尽可能达到最大的萃取效益,视需要地,可于进行步骤(b)之前,以相同或不同的第一极性溶剂对茯苓重复进行萃取,并合并该多次萃取所得的萃取液以提供进行步骤(b)的粗萃物;也可重复进行步骤(b)、步骤(c)、以及前述视需要的其它操作的循环。
如后附实施例所示,根据本发明,可由茯苓萃取物中纯化分离出去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B等成分。其中,根据本发明所提供的茯苓皮部萃取物含有去氢土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A、以及茯苓新酸B等成分。
本案发明人进一步研究发现,去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B都可有效促进细胞表现胶原蛋白及/或透明质酸(即,提升内源性胶原蛋白及/或透明质酸的含量),故可用于保养肌肤及促进伤口愈合。因此,本发明也关于一种使用一活性成分于保养肌肤及/或促进伤口愈合的应用,其中该活性成分选自以下的至少一者:去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B。前述应用包括使用该活性成分以制备一用于保养肌肤及/或促进伤口愈合的制剂的用途、对有需要的个体投予该活性成分以保养肌肤及/或促进伤口愈合的方法、以及提供一包含该活性成分的组合物。较佳地,根据本发明所采用的活性成分以萃取物的形式提供;更佳地,该活性成分以真菌萃取物或植物萃取物的形式提供。
于根据本发明的应用,该制剂或组合物可以一化妆品、保养品、食品、或药剂的形式提供。当以一化妆品或保养品的形式提供该制剂或组合物时,该化妆品或保养品可呈任何合宜的形式,并无特殊的限制,视所欲的用途而呈对应的合宜剂型。举例言之,但不以此为限,该化妆品或保养品可呈供直接外用的乳液、乳霜、凝胶(例如水凝胶)、膏状物(例如分散膏、软膏)、喷雾剂、或溶液(例如洗液、悬浮液)等形式。或者,可将本发明的制剂或组合物制备成可供吞食或饮用的食品形式,例如健康食品、美容饮品等。此外,也可将本发明制剂或组合物以皮下注射的针剂形式提供。
类似地,当以一药剂的形式提供该根据本发明的制剂或组合物时,该药剂可呈任何合宜的形式,并无特殊限制,视所欲的用途而呈对应的合宜剂型。举例言之,但不以此为限,该药剂可以口服或非经口服(例如:经皮、皮下、或静脉内)的投药方式施用至有需要的个体上,以保养肌肤及/或促进伤口愈合。其中,视使用形式及用途而定,可选用合宜的载剂以提供该药剂,其中,该载剂包括赋形剂、稀释剂、辅助剂、安定剂、吸收延迟剂、崩散剂、增溶剂、乳化剂、抗氧化剂、粘合剂、结合剂、增粘剂、分散剂、悬浮化剂、润滑剂、及╱或吸湿剂等。
以适于口服投药的药剂形式为例,该药剂中可含有任何不会不利影响所含有活性成分(即,茯苓萃取物、去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B的至少一者)的所欲效益的医药上可接受的载剂,该载剂可以例如选自以下群组:水、食盐水、葡萄糖(dextrose)、甘油、乙醇或其类似物、纤维素、淀粉、糖膨润土(sugar bentonite)、及前述的组合。可利用任何合宜的方法,以适于口服投药的剂型提供该药剂,例如:锭剂(例如糖衣锭)、丸剂、胶囊剂、颗粒剂、散剂、流浸膏剂、溶液剂、糖浆剂、悬液剂、酊剂等。
至于适于皮下或静脉内的针剂或点滴剂型,则可于该药剂中含有一或多种例如等张溶液、盐类缓冲液(如磷酸盐缓冲液或柠檬酸盐缓冲液)、增溶剂、乳化剂、5%糖溶液、以及其他载剂等成分,以静脉输注液、乳剂静脉输注液、干粉注射剂、悬液注射剂、或干粉悬液注射剂等剂型提供该药剂。或者,将该药剂制备成一注射前固体,以可溶于其他溶液或悬浮液中的剂型、或可乳化的剂型提供该注射前固体,并于投予至有需要的个体之前,将该注射前固体溶于其他溶液或悬浮液中或将其乳化,以提供所欲的注射剂。
视需要地,可于根据本发明所提供的制剂或组合物中另外含有合宜用量的添加剂,例如可提高该制剂或组合物于服用时的口适感及视觉感受的调味剂、调色剂、着色剂等,以及可改善该制剂或组合物的稳定性及储存性的缓冲剂、保存剂、防腐剂、抗菌剂、抗真菌剂等。此外,该制剂或组合物可视需要另外含有一或多种其他活性成分(例如,胶原蛋白、透明质酸、弹性蛋白、杏仁酸、熊果素等),或者与含有该一或多种其他活性成分的保养品或药物并用,以进一步加强该制剂或组合物的功效或增加该制剂或组合物配方的运用灵活性与调配度。原则上,只要所添加的其它成分或添加剂不会对本发明制剂或组合物的所欲功效没有不利的影响即可。
于根据本发明的应用所提供的制剂或组合物可以一日一次、一日多次、或数日一次等不同频率施用,视投予个体的需求、年龄、体重、健康况状、及施用目的而异。
本发明也提供一种用于保养肌肤及/或促进伤口愈合的方法,其包含对一有需要的个体投予一有效量的活性成分(即,茯苓萃取物、去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B的至少一者)。于根据本发明的保养肌肤及/或促进伤口愈合的方法中,有关该活性成分的实施例、投予途径、投予形式、适用剂量、以及相关应用,均如上述的说明。
现以下列实施例进一步例示说明本发明。其中这些实施例仅提供作为说明,而非用以限制本发明的保护范围。本发明的保护范围如权利要求书所示。
实施例
制备实施例
A.茯苓萃取物的制备
A-1.取茯苓药材(来源产地为云南),清洗后剥取其外皮(下称“茯苓皮部”),其余即为肉部(下称“茯苓肉部”)。
取 A-1 所获得的茯苓皮部,于室温下,以1:8(茯苓药材:乙醇水溶液)的体积比浸泡于75%乙醇水溶液中,历时12小时,然后煮沸并进行萃取(历时3小时)。重复前述萃取步骤,共三次。合并三次萃取所得的萃取液并过滤以去除不溶物,以获得一粗萃取物。接着,对前述的粗萃取物进行减压浓缩以去除溶剂,再以喷雾干燥机进行干燥,以获得一粗萃物粉末。
取 A-2 所获得的粗萃物粉末,以1:8(粗萃物粉末:乙醇水溶液)的体积比与95%乙醇混合,并进行萃取(历时3小时),接着,再利用以硅胶为固定相的管柱进行分离,获得一茯苓皮部萃取物。
以液相层析/紫外光/质谱仪,分别于243纳米及210纳米波长下检测 A-3 所获得的茯苓皮部萃取物的成分,并以高效液相色谱法定量该萃取物中各成分的含量,分析结果示于表1。
表1
成分 | 重量% |
茯苓酸(pachymic acid,PA) | - |
去氢茯苓酸(dehydropachymic acid,DPA) | - |
土莫酸(tumulosic acid,TA) | - |
去氢土莫酸(dehydrotumulosic acid,DTA) | 0.46 |
猪苓酸C(polyporenic acid C,PAC) | 2.01 |
3-表-去氢土莫酸(3-epi-dehydrotumulosic acid,EDTA) | 0.77 |
去氢栓菌酸(dehydrotrametenolic acid,DTTA) | 2.01 |
栓菌酸(trametenolic acid,TTA) | 0.85 |
茯苓新酸A(poricoic acid A,PAA) | 32.72 |
去氢层孔菌酸(dehydroeburicoic acid,DEA) | 1.20 |
茯苓新酸B(poricoic acid B,PAB) | 10.44 |
层孔菌酸(eburicoic acid,EA) | 0.83 |
A-5.合并 A-1 所获得的茯苓皮部及茯苓肉部,重复上述 A-2 及 A-3的萃取步骤,以获得一茯苓萃取物。接着,以 A-4 的分析方法检测所获得的茯苓萃取物的成分。结果显示,该茯苓萃取物含有去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B等成分。
茯苓萃取物的活性成分的制备
B-1.以1:500(萃取物:甲醇)的体积比,将 A-5 所获得的茯苓萃取物均匀溶解于甲醇中。过滤去除不溶物后,以制备级高效能液相层析仪(以甲醇与水混合作为移动相),分别于243纳米及210纳米波长下,针对去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B进行分离及收集,收集后再以减压浓缩机去除甲醇,分别得到去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B。
以液相层析/紫外光/质谱仪,分别于243纳米及210纳米波长下检测B-1所获得的去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B,结果显示这些成分的纯度都大于98%。
细胞培养
将正常人类皮肤初代纤维母细胞(normal primary human skin fibroblastic cell,购自ATCC)培养在纤维母细胞生长培养基(Fibroblast Growth Medium)培养基中,以供后续实验使用。
实施例1:茯苓萃取物对细胞表现胶原蛋白及透明质酸的能力的影响
取[制备实施例C]所提供的正常人类皮肤初代纤维母细胞,将其分成四组并分别以如下培养基进行培养,历时48小时:
1. 第I组:纤维母细胞生长培养基;
2.第II组:含有0.005微克/毫升[制备实施例A-3]所提供的茯苓皮部萃取物的纤维母细胞生长培养基;
3. 第III组:含有0.05微克/毫升[制备实施例A-3]所提供的茯苓皮部萃取物的纤维母细胞生长培养基;
4. 第IV组:含有0.5微克/毫升[制备实施例A-3]所提供的茯苓皮部萃取物的纤维母细胞生长培养基。
其后,收集各组细胞培养液并加以浓缩,再以西方墨点法及酵素免疫分析法(ELISA)进行分析,测定各组的细胞内胶原蛋白的含量、细胞培养液中(即,细胞外)胶原蛋白的含量、以及细胞培养液中透明质酸的含量。最后,以控制组(即,经第I组培养液培养的细胞)的结果为100%,计算其他各组的胶原蛋白及透明质酸的相对含量(以百分比表示),结果示于表2。
表2
第II组 | 第III组 | 第IV组 | |
细胞内胶原蛋白(%) | 152 | 182 | 200 |
细胞培养液中胶原蛋白(%) | 116 | 156 | 135 |
细胞培养液中透明质酸(%) | 131 | 121 | 106 |
由表2可知,相较于控制组,经本发明茯苓萃取物处理的细胞(即,以第II、III、或IV组培养液培养的细胞)的细胞内胶原蛋白含量、细胞培养液中(即,细胞外)胶原蛋白含量、以及细胞培养液中的透明质酸含量都显著提升。前述结果显示,本发明茯苓萃取物可有效提升纤维母细胞表现胶原蛋白及/或透明质酸的能力(即,提升内源性胶原蛋白及/或透明质酸的含量),故可用于保养皮肤及/或促进伤口愈合。
实施例2:茯苓萃取物的活性成分对细胞表现胶原蛋白及透明质酸的能力的影响
(2-1)细胞内的胶原蛋白表现
取[制备实施例C]所提供的正常人类皮肤初代纤维母细胞,将其分成三十七组,分别以如下培养基进行培养,历时48小时:
1. 第1组:纤维母细胞生长培养基;
2. 第2-1至2-3组:含有[制备实施例B]所提供的茯苓酸(PA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
3. 第3-1至3-3组:含有[制备实施例B]所提供的去氢茯苓酸(DPA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
4. 第4-1至4-3组:含有[制备实施例B]所提供的土莫酸(TA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
5. 第5-1至5-3组:含有[制备实施例B]所提供的去氢土莫酸(DTA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
6. 第6-1至6-3组:含有[制备实施例B]所提供的猪苓酸C(PAC)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
7. 第7-1至7-3组:含有[制备实施例B]所提供的3-表-去氢土莫酸(EDTA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
8. 第8-1至8-3组:含有[制备实施例B]所提供的去氢栓菌酸(DTTA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
9. 第9-1至9-3组:含有[制备实施例B]所提供的栓菌酸(TTA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
10. 第10-1至10-3组:含有[制备实施例B]所提供的茯苓新酸A(PAA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
11. 第11-1至11-3组:含有[制备实施例B]所提供的去氢层孔菌酸(DEA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
12. 第12-1至12-3组:含有[制备实施例B]所提供的茯苓新酸B(PAB)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度;
13. 第13-1至13-3组:含有[制备实施例B]所提供的层孔菌酸(EA)的纤维母细胞生长培养基,浓度分别为0.01、0.1、及1微摩尔浓度。
其后,收集各组细胞培养液并加以浓缩,再以西方墨点法及酵素免疫分析法(ELISA)进行分析,测定各组的细胞内胶原蛋白的含量。最后,以控制组(即,经第1组培养液培养的细胞)的结果为100%,计算其他各组的胶原蛋白的相对含量(以百分比表示),结果示于表3。
表3
由表3可知,相较于控制组,经茯苓酸、去氢茯苓酸、土莫酸、去氢土莫酸、猪苓酸C、去氢栓菌酸、或茯苓新酸A处理的细胞,其细胞内的胶原蛋白的含量都显著提升。前述结果显示,茯苓酸、去氢茯苓酸、土莫酸、去氢土莫酸、猪苓酸C、去氢栓菌酸、及茯苓新酸A可有效提升纤维母细胞表现胶原蛋白的能力(即,提升内源性胶原蛋白及/或透明质酸的含量),故可用于保养皮肤及/或促进伤口愈合。
(2-2)细胞外的胶原蛋白表现
为了解本发明活性成分对细胞外的胶原蛋白表现的影响,以西方墨点法及酵素免疫分析法(ELISA),对实施例(2-1)所提供的经浓缩的各组细胞培养液进行分析,测定各组培养液中(即,细胞外)的胶原蛋白含量。最后,以控制组(即,经第1组培养液培养的细胞)的结果为100%,计算其他各组的胶原蛋白的相对含量(以百分比表示),结果示于表4。
表4
由表4可知,相较于控制组,经去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A、及茯苓新酸B处理的细胞,其细胞外的胶原蛋白的含量都显著提升。前述结果显示,本发明活性成分可有效提升纤维母细胞表现及分泌胶原蛋白的能力,故可用于保养皮肤及/或促进伤口愈合。
(2-3)细胞外的透明质酸表现
为了解本发明活性成分对细胞外的透明质酸表现的影响,以西方墨点法及酵素免疫分析法(ELISA),对实施例(2-1)所提供的经浓缩的各组细胞培养液进行分析,测定各组培养液中(即,细胞外)的透明质酸含量。最后,以控制组(即,经第1组培养液培养的细胞)的结果为100%,计算其他各组的透明质酸的相对含量(以百分比表示),结果示于表5。
表5
由表5可知,相较于控制组,经去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A或茯苓新酸B处理的细胞,其细胞外的透明质酸的含量都显著提升,其中,经茯苓酸、去氢茯苓酸、土莫酸、去氢土莫酸、及3-表-去氢土莫酸处理的细胞的提升效果特别显著。前述结果显示,本发明活性成分可有效提升纤维母细胞表现透明质酸的能力,故可用于保养皮肤。
如上述实施例所示,本发明茯苓萃取物及/或其活性成分确实可提升细胞表现胶原蛋白及透明质酸的能力(即,具有提升内源性胶原蛋白及透明质酸的含量的能力),可用于保养皮肤(包括滋润肌肤、紧实肌肤、修复肌肤、保湿、淡化皱纹、延缓肌肤老化、及预防肌肤老化)及/或促进伤口愈合。
Claims (14)
1.一种使用茯苓萃取物于制备一制剂的用途,其特征在于:该制剂用于保养肌肤及/或促进伤口愈合。
2.如权利要求1所述的用途,其特征在于:该茯苓萃取物包含以下的至少一者:去氢茯苓酸(dehydropachymic acid,DPA)、茯苓酸(pachymic acid,PA)、去氢土莫酸(dehydrotumulosic acid,DTA)、土莫酸(tumulosic acid,TA)、猪苓酸C(polyporenicacid C,PAC)、3-表-去氢土莫酸(3-epi-dehydrotumulosic acid,EDTA)、去氢栓菌酸(dehydrotrametenolic acid,DTTA)、栓菌酸(trametenolic acid,TTA)、去氢层孔菌酸(dehydroeburicoic acid,DEA)、层孔菌酸(eburicoic acid,EA)、茯苓新酸A(poricoicacid A,PAA)及茯苓新酸B(poricoic acid B,PAB)。
3.如权利要求1所述的用途,其特征在于:该茯苓萃取物为茯苓皮部萃取物。
4.如权利要求3所述的用途,其特征在于:以茯苓皮部萃取物的总重量计,茯苓新酸A及茯苓新酸B的总含量不小于40重量%。
5.如权利要求1至4中任一项所述的用途,其特征在于:该制剂以一化妆品、保养品或食品的形式提供,且通过提升胶原蛋白及/或透明质酸的表现以保养肌肤。
6.如权利要求5所述的用途,其特征在于:该化妆品、保养品及食品用于以下的至少一者:滋润肌肤、紧实肌肤、修复肌肤、保湿、淡化皱纹、延缓肌肤老化、及预防肌肤老化。
7.如权利要求1至4中任一项所述的用途,其特征在于:该制剂以一药剂的形式提供,且通过提升胶原蛋白及/或透明质酸的表现以促进伤口愈合。
8.一种使用一活性成分于制备一用于保养肌肤及/或促进伤口愈合的制剂的用途,其特征在于:该活性成分选自以下的至少一者:去氢茯苓酸、茯苓酸、去氢土莫酸、土莫酸、猪苓酸C、3-表-去氢土莫酸、去氢栓菌酸、栓菌酸、去氢层孔菌酸、层孔菌酸、茯苓新酸A及茯苓新酸B。
9.如权利要求8所述的用途,其特征在于:该活性成分为茯苓新酸A及/或茯苓新酸B。
10.如权利要求8所述的用途,其特征在于:该活性成分以萃取物的形式提供。
11.如权利要求10所述的用途,其特征在于:该活性成分以真菌萃取物或植物萃取物的形式提供。
12.如权利要求8至11中任一项所述的用途,其特征在于:该制剂以一化妆品、保养品或食品的形式提供,且通过提升胶原蛋白及/或透明质酸的表现以保养肌肤。
13.如权利要求12所述的用途,其特征在于:该化妆品、保养品及食品用于以下的至少一者:滋润肌肤、紧实肌肤、修复肌肤、保湿、淡化皱纹、延缓肌肤老化、及预防肌肤老化。
14.如权利要求8至11中任一项所述的用途,其特征在于:该制剂以一药剂的形式提供,且通过提升胶原蛋白及/或透明质酸的表现以促进伤口愈合。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662383860P | 2016-09-06 | 2016-09-06 | |
US62/383,860 | 2016-09-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107789373A true CN107789373A (zh) | 2018-03-13 |
Family
ID=61281841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710789742.0A Pending CN107789373A (zh) | 2016-09-06 | 2017-09-05 | 茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11654169B2 (zh) |
JP (1) | JP6798030B2 (zh) |
KR (1) | KR102295786B1 (zh) |
CN (1) | CN107789373A (zh) |
MY (1) | MY195806A (zh) |
TW (1) | TWI640317B (zh) |
WO (1) | WO2018045943A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111632056A (zh) * | 2020-06-04 | 2020-09-08 | 广东省农业科学院动物卫生研究所 | 松苓新酸及其衍生物在制备抗柔嫩艾美耳球虫的药物中的应用 |
CN114631604A (zh) * | 2020-11-30 | 2022-06-17 | 百岳特生物技术(上海)有限公司 | 植物发酵液改善睡眠质量及/或抗老化的用途 |
TWI784357B (zh) * | 2020-11-30 | 2022-11-21 | 大江生醫股份有限公司 | 植物發酵液改善睡眠品質及/或抗老化的用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102611023B1 (ko) * | 2018-11-21 | 2023-12-08 | (주)아모레퍼시픽 | 탈수소 아비에틱산을 포함하는 피부 장벽 강화용 또는 보습용 피부 외용제 조성물 |
CN114146019B (zh) * | 2021-12-29 | 2023-04-18 | 上海应用技术大学 | 一种茯苓多糖提取物及其在抗紫外线中的应用 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0940552A (ja) * | 1995-08-02 | 1997-02-10 | Kanebo Ltd | ヒトコラゲナーゼ活性阻害剤 |
JPH10237093A (ja) * | 1997-02-28 | 1998-09-08 | Kotarou Kanpo Seiyaku Kk | マツホド抽出成分を含む抗炎症剤 |
DE10151649A1 (de) * | 2001-10-11 | 2003-05-08 | Peter Elsner | Verwendung von Lanostanen als Inhibitoren von 3alpha-Hydroxysteroid-Dehydrogenase und Cyclooxygenasen |
US20030124159A1 (en) * | 2001-10-04 | 2003-07-03 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc | Enhancing epidermal barrier development in skin |
US20090318399A1 (en) * | 2008-06-20 | 2009-12-24 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder |
CN101621986A (zh) * | 2007-02-28 | 2010-01-06 | 株式会社太平洋 | 含有北玄参提取物的皮肤外用组合物以及该组合物用作皮肤保湿化妆品的应用 |
CN103974715A (zh) * | 2011-06-17 | 2014-08-06 | 哈洛齐梅公司 | 乙酰透明质酸降解酶的稳定制剂 |
KR20150057898A (ko) * | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | 피부 재생, 주름개선, 항염증 또는 피부 미백용 조성물 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2708466B1 (fr) * | 1993-06-30 | 1995-10-27 | Lvmh Rech | Utilisation d'un extrait de champignons Poria cocos Wolf pour la préparation d'une composition cosmétique ou pharmaceutique, notamment dermatologique pour le traitement de l'acné ou des peaux grasses. |
JPH08119864A (ja) * | 1994-09-02 | 1996-05-14 | Kotarou Kanpo Seiyaku Kk | 鎮吐薬 |
JPH0925232A (ja) * | 1995-07-14 | 1997-01-28 | Kotarou Kanpo Seiyaku Kk | 発癌予防剤 |
JPH10330266A (ja) * | 1997-06-02 | 1998-12-15 | Kotarou Kanpo Seiyaku Kk | インスリン作用増強活性組成物 |
JP2003104905A (ja) * | 2001-09-28 | 2003-04-09 | Nagatomo Yakuhin:Kk | 茸有効成分の抽出方法 |
JP2008105972A (ja) * | 2006-10-24 | 2008-05-08 | Nagatomo Yakuhin:Kk | 生薬の抗腫瘍性有効物質の抽出法 |
US7992280B2 (en) * | 2008-01-07 | 2011-08-09 | Mssc Us | Method of casting metal anti-shift collars for stabilizer bar |
TWI441640B (zh) * | 2008-03-31 | 2014-06-21 | Sinphar Pharmaceutical Co Ltd | 促進營養素被吸收的醫藥組合物及茯苓萃取物 |
US20100233301A1 (en) * | 2009-03-11 | 2010-09-16 | Jing Cheng | Topical compositions comprising fermented extracts of traditional chinese medicinal (tcm) ingredients, and methods of making and using same |
CN101874807B (zh) * | 2009-05-02 | 2013-04-10 | 杏辉天力(杭州)药业有限公司 | 以羊毛固醇及茯苓萃取物治疗恶病质的用途 |
AU2010350888B2 (en) * | 2010-04-12 | 2015-10-29 | Chemisches Laboratorium Dr. Kurt Richter Gmbh | Active substance complex and formulation comprising it |
JP5675178B2 (ja) * | 2010-06-09 | 2015-02-25 | 大島 光宏 | コラーゲン分解阻害剤 |
TWI513475B (zh) | 2012-08-31 | 2015-12-21 | Uni President Biotech Co Ltd | 具有亮白、保濕、撫平細紋、緊緻肌膚及調理柔膚功能的紅景天組合物 |
CN103550265B (zh) * | 2013-11-08 | 2015-07-01 | 山东省中医药研究院 | 一种茯苓皮有效成分的提取方法及其提取物 |
US9370540B2 (en) | 2014-05-21 | 2016-06-21 | Sinphar Pahrmaceutical Co., Ltd. | K2 composition and the preparation method and use of the same |
KR102178888B1 (ko) * | 2014-07-01 | 2020-11-16 | 주식회사 엘지생활건강 | 한약재 추출물을 포함하는 피부 탄력 증진 또는 주름 개선용 화장료 조성물 |
KR20160057196A (ko) | 2014-11-13 | 2016-05-23 | 주식회사심비오즈코스메틱스 | Pachymic acid를 유효성분으로 함유하는 피부 미백 화장료 조성물 |
KR101671437B1 (ko) * | 2014-12-19 | 2016-11-01 | 동아에스티 주식회사 | 상심자 및 복령피 혼합 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
KR101698163B1 (ko) * | 2014-12-19 | 2017-01-19 | 동아에스티 주식회사 | 복령피 추출물을 함유하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
CN104688782B (zh) | 2015-02-05 | 2018-05-04 | 广东药科大学 | 一种从茯苓皮中高效提取三萜类活性成分的方法 |
CN105147592B (zh) | 2015-10-16 | 2018-11-13 | 湖北穆兰同大科技有限公司 | 一种含有白茯苓的面膜及其制备方法 |
CN105639617A (zh) | 2015-12-31 | 2016-06-08 | 湖南诺泽生物科技有限公司 | 一种茯苓的综合开发和应用的方法及其新用途 |
-
2017
- 2017-09-05 WO PCT/CN2017/100526 patent/WO2018045943A1/zh active Application Filing
- 2017-09-05 CN CN201710789742.0A patent/CN107789373A/zh active Pending
- 2017-09-05 KR KR1020197009564A patent/KR102295786B1/ko active IP Right Grant
- 2017-09-05 TW TW106130209A patent/TWI640317B/zh active
- 2017-09-05 MY MYPI2019001172A patent/MY195806A/en unknown
- 2017-09-05 US US15/695,527 patent/US11654169B2/en active Active
- 2017-09-05 JP JP2019533271A patent/JP6798030B2/ja active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0940552A (ja) * | 1995-08-02 | 1997-02-10 | Kanebo Ltd | ヒトコラゲナーゼ活性阻害剤 |
JPH10237093A (ja) * | 1997-02-28 | 1998-09-08 | Kotarou Kanpo Seiyaku Kk | マツホド抽出成分を含む抗炎症剤 |
US20030124159A1 (en) * | 2001-10-04 | 2003-07-03 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc | Enhancing epidermal barrier development in skin |
DE10151649A1 (de) * | 2001-10-11 | 2003-05-08 | Peter Elsner | Verwendung von Lanostanen als Inhibitoren von 3alpha-Hydroxysteroid-Dehydrogenase und Cyclooxygenasen |
CN101621986A (zh) * | 2007-02-28 | 2010-01-06 | 株式会社太平洋 | 含有北玄参提取物的皮肤外用组合物以及该组合物用作皮肤保湿化妆品的应用 |
US20090318399A1 (en) * | 2008-06-20 | 2009-12-24 | Sinphar Pharmaceutical Co., Ltd. | Pharmaceutical composition and extract of poria for treating a disease induced from immune disorder |
CN103974715A (zh) * | 2011-06-17 | 2014-08-06 | 哈洛齐梅公司 | 乙酰透明质酸降解酶的稳定制剂 |
KR20150057898A (ko) * | 2013-11-18 | 2015-05-28 | 주식회사 엘지생활건강 | 피부 재생, 주름개선, 항염증 또는 피부 미백용 조성물 |
Non-Patent Citations (2)
Title |
---|
程水明等: ""茯苓皮三萜抑制酪氨酸酶机理研究"", 《食品研究与开发》 * |
程水明等: ""茯苓皮三萜类物质抗氧化活性研究"", 《食品科学》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111632056A (zh) * | 2020-06-04 | 2020-09-08 | 广东省农业科学院动物卫生研究所 | 松苓新酸及其衍生物在制备抗柔嫩艾美耳球虫的药物中的应用 |
CN114631604A (zh) * | 2020-11-30 | 2022-06-17 | 百岳特生物技术(上海)有限公司 | 植物发酵液改善睡眠质量及/或抗老化的用途 |
TWI784357B (zh) * | 2020-11-30 | 2022-11-21 | 大江生醫股份有限公司 | 植物發酵液改善睡眠品質及/或抗老化的用途 |
Also Published As
Publication number | Publication date |
---|---|
TWI640317B (zh) | 2018-11-11 |
JP2019529533A (ja) | 2019-10-17 |
KR20190064580A (ko) | 2019-06-10 |
WO2018045943A1 (zh) | 2018-03-15 |
MY195806A (en) | 2023-02-22 |
US11654169B2 (en) | 2023-05-23 |
US20180064771A1 (en) | 2018-03-08 |
TW201811350A (zh) | 2018-04-01 |
KR102295786B1 (ko) | 2021-09-01 |
JP6798030B2 (ja) | 2020-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107789373A (zh) | 茯苓萃取物及其活性成分于保养肌肤及/或促进伤口愈合的用途 | |
JP6411580B2 (ja) | 三白草抽出物を含有する皮脂生成抑制用組成物 | |
JP2003238432A (ja) | ヒアルロン酸蓄積促進剤 | |
KR20130031704A (ko) | 버섯배지를 이용한 차가버섯, 상황버섯, 영지버섯, 꽃송이버섯 및 동충하초의 복합배양방법 | |
JP2019529533A5 (zh) | ||
CN112535652A (zh) | 一种光感赋活原液及其制备方法 | |
KR101295368B1 (ko) | 허니부쉬 추출물 또는 이의 발효액을 유효성분으로 함유하는 피부 주름 개선용 조성물 | |
KR20190088286A (ko) | 아스페르길루스 크리스타투스 균주로 발효시킨 발효 콩의 추출물을 포함하는 피부미용 개선용 조성물 | |
KR101458274B1 (ko) | 인삼 발효추출물을 함유하는 화장료 조성물 | |
KR102101949B1 (ko) | 우장지버섯 자실체 추출물 또는 우장지버섯 균사체 추출물을 함유하는 피부 외용제 또는 화장료 조성물 | |
CN108567632A (zh) | 茶树愈伤组织萃取物于护肤的用途 | |
KR102137136B1 (ko) | 호박 가수분해 추출물, 구약감자 가수분해 추출물, 강황 추출물 및 카카오닙스 추출물을 포함하는 조성물 | |
KR20120131065A (ko) | 아위느타리버섯 추출물 또는 이의 분획물을 유효성분으로 함유하는 노화 예방 또는 개선용 조성물 | |
KR20230120619A (ko) | 피부 상태 개선용 조성물 | |
JP5818303B2 (ja) | 抗酸化剤の製造方法およびその用途 | |
CN105963674A (zh) | 一种天然细胞修复剂及其制备方法 | |
KR102067283B1 (ko) | 곰보버섯 자실체 추출물 또는 곰보버섯 균사체 추출물을 함유하는 피부 외용제 또는 화장료 조성물 | |
KR101853711B1 (ko) | 파이퍼 캄보디아눔 추출물을 포함하는 피부개선용 화장료 조성물 | |
KR102073943B1 (ko) | 만가닥버섯 자실체 추출물 또는 만가닥버섯 균사체 추출물을 함유하는 피부 외용제 또는 화장료 조성물 | |
JP7365664B2 (ja) | 真皮幹細胞の分化促進剤 | |
KR102124065B1 (ko) | 식물 추출물을 함유하는 피부 주름 개선용 조성물 | |
JP2020174543A (ja) | 表皮幹細胞の分化促進剤 | |
CN108261429A (zh) | 茯苓萃取物及其活性成分于调节、预防及/或治疗肺部损伤的用途 | |
CN107349192A (zh) | 茯苓皮部萃取物、茯苓新酸a、及茯苓新酸b于调节血糖的用途 | |
KR102632060B1 (ko) | 발아 흑미 및 발효 돼지감자 복합 추출물을 포함하는 탈모 예방용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180313 |
|
RJ01 | Rejection of invention patent application after publication |